- Home
- SIG vs CNTA Comparison
SIG vs CNTA Comparison
Compare SIG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIG | CNTA |
|---|---|---|
| Founded | 1950 | 2020 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SIG | CNTA |
|---|---|---|
| Price | $88.25 | $39.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $111.14 | $42.00 |
| AVG Volume (30 Days) | 1.1M | ★ 4.0M |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ 974.07 | 29.13 |
| EPS | ★ 7.08 | N/A |
| Revenue | ★ $6,247,100,000.00 | $15,000,000.00 |
| Revenue This Year | $2.22 | N/A |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $11.98 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.02 | $9.60 |
| 52 Week High | $110.20 | $40.26 |
Technical Indicators
Market Signals| Indicator | SIG | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 77.47 |
| Support Level | $79.54 | $22.49 |
| Resistance Level | $95.10 | N/A |
| Average True Range (ATR) | 4.62 | 1.42 |
| MACD | 0.21 | 1.33 |
| Stochastic Oscillator | 64.23 | 96.39 |
Price Performance
Historical ComparisonAbout SIG Signet Jewelers Limited
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Off-Mall & Outlet.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.